Regulation of Adrenal Aldosterone Production by Serine Protease Prostasin by Ko, Takehiro et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 793843, 9 pages
doi:10.1155/2010/793843
Research Article
Regulation of Adrenal Aldosterone Production by
SerineProtease Prostasin
Takehiro Ko,1 YutakaKakizoe,1 Naoki Wakida,1 Manabu Hayata,1 Kohei Uchimura,1
Naoki Shiraishi,1 Taku Miyoshi,1 MasatakaAdachi,1 ShizukaAritomi,2 Tomoyuki Konda,2
Kimio Tomita,1 and KenichiroKitamura1
1Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, Kumamoto,
Kumamoto 860-8556, Japan
2Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki, Kawasaki 210-8681, Japan
Correspondence should be addressed to Kenichiro Kitamura, ken@gpo.kumamoto-u.ac.jp
Received 25 September 2009; Revised 11 November 2009; Accepted 23 November 2009
Academic Editor: Karl Chai
Copyright © 2010 Takehiro Ko et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A serine protease prostasin has been demonstrated to have a pivotal role in the activation of the epithelial sodium channel.
Systemic administration of adenovirus carrying human prostasin gene in rats resulted in an increase in plasma prostasin and
aldosterone levels. However, the mechanism by which the elevation of prostasin levels in the systemic circulation stimulated the
plasma aldosterone levels remains unknown. Therefore, we examined if prostasin increases the aldosterone synthesis in a human
adrenocortical cell line (H295R cells). Luciferase assay using CYP11B2 promoter revealed that prostasin signiﬁcantly increased
the transcriptional activity of CYP11B2. Prostasin signiﬁcantly increased both CYP11B2 mRNA expression and aldosterone
productioninadose-dependentmanner.Surprisingly,treatmentwithcamostatmesilate,apotentprostasininhibitor,hadnoeﬀect
on the aldosterone synthesis by prostasin and also a protease-dead mutant of prostasin signiﬁcantly stimulated the aldosterone
production. A T-type/L-typecalcium channel blocker and a protein kinase C (PKC)inhibitor signiﬁcantly reduced the aldosterone
synthesis by prostasin. Our ﬁndings suggest a stimulatory eﬀect of prostasin on the aldosterone synthesis by adrenal gland through
the nonproteolytic action and indicate a new role of prostasin in the systemic circulation.
1.Introduction
Proteases are involved in numerous essential biologi-
cal processes including blood clotting, controlled cell
death, and tissue diﬀerentiation. Prostasin is a glyco-
sylphosphatidylinositol-(GPI-)anchoredand/orsecretedser-
ine protease puriﬁed from human seminal ﬂuid [1]a n d
is expressed in the kidney, prostate, liver, lung, pancreas,
and colon [2]. Prostasin has been identiﬁed as a potential
regulator of the epithelial sodium channel function in
the kidney, lung, and airways. Previously we showed that
aldosteroneincreasedprostasinabundanceinratandhuman
[3] and also demonstrated a positive relationship between
urinary prostasin levels and plasma or urinary aldosterone
levels in human [4]. GPI-anchor free form of prostasin is
also found in serum, but the physiological role of prostasin,
especially in the systemic circulation, remains largely unde-
termined. In 2003, Wang et al. demonstrated that systemic
administration of adenovirus carrying human prostasin
gene in rats resulted in an elevation of plasma prostasin
levels, plasma aldosterone concentration, and blood pressure
[5]. However, the mechanism by which prostasin increases
plasma aldosterone levels remains to be elucidated.
The adrenal cortex is the site of synthesis of the potent
mineralocorticoid, aldosterone, and the glucocorticoid, cor-
tisol. Aldosterone synthase (CYP11B2), which is expressed
only within the zona glomerulosa of the adrenal cortex,
is responsible for converting deoxycorticosterone to aldos-
terone [6–9]. The two most important physiological stimuli
of aldosterone secretion, angiotensin II and extracellular K+
[10], exert their eﬀects through generating cytoplasmic Ca2+
signal. Meanwhile, proteolytic enzymes such as trypsin have2 Journal of Biomedicine and Biotechnology
also been demonstrated to stimulate aldosterone secretion
directly from intact rat adrenal capsular tissue [11–13].
Although the molecular mechanisms by which trypsin
activates aldosterone production in adrenal cortex remain
to be clariﬁed, a possible involvement of protease-activated
receptor-1 (PAR-1) has been suggested [14].
Therefore, in the current studies we hypothesized that
serineproteaseprostasinincreasesaldosteroneproductionby
the adrenal gland and investigated the eﬀect of prostasin on
CYP11B2 expression and aldosterone production in H295R
cells. We also examined a possible molecular mechanism by
which prostasin activates aldosterone production.
2. Methods
2.1. Reagents. A protein kinase C inhibitor, Ro-31-8220, was
purchased from Sigma-Aldrich (St Louis, MO, USA). Camo-
statmesilatewaskindlysuppliedbyOnoPharmaceuticalCo.,
Ltd. (Osaka, Japan). Efonidipine hydrochloride was from
Shionogi & Co., Ltd. (Osaka, Japan), and Valsartan was from
Novartis Pharma K.K. (Tokyo, Japan).
2.2. Puriﬁcation of Wild Type and Protease-Dead Recombinant
Human Prostasin. Wild type recombinant human prostasin
was prepared as described previously [15]. Brieﬂy, a cDNA
forrecombinanthumanprostasinwascreatedbyinsertingan
enterokinase cleavage site, Asp-Asp-Asp-Asp-Lys, between
the light chain and heavy chain and by replacing the C-
terminal membrane anchoring domain with a 6 × His tag.
To generate protease-dead mutant prostasin, catalytic triad
of prostasin, His85, Asp134, and Ser238 were all replaced
by Ala using QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA). Recombinant baculovirus
carrying these cDNAs were developed and silkworm larvae
were infected with these virus. After infection, hemolymph
was collected and recombinant prostasin was puriﬁed by
using a Ni-sepharose column (HisTrap HP: GE Healthcare
Bio-Sciences, Piscataway, NJ, USA), an ion exchange column
(HiTrap Q: GE Healthcare Bio-Sciences), and a gel ﬁltration
column (Superdex 200 10/300 GL: GE Healthcare Bio-
Sciences). Puriﬁed recombinant prostasin was treated with
enterokinase (EK Max: Invitrogen, Carlsbad, CA, USA) at
37
◦C to generate mature recombinant prostasin by cleaving
theenterokinasecleavagesite.Theenterokinasewasremoved
from the reaction mixture by enterokinase removal kit
(Sigma-Aldrich). Proteolytic activity of prostasin was deter-
mined by the enzymatic assay as described previously [4].
2.3. Cell Culture. The H295R human adrenocortical cell line
was purchased from the American Type Culture Collection
(Manassas, VA, USA) and cultured in DMEM/F12 medium
(Gibco Invitrogen, Burlington, ON, Canada) containing
2.5% NuSerum (BD Biosciences, Bedford, MA, USA), 1%
ITS (BD Biosciences). The cells were maintained at 37
◦C
under a humid atmosphere of 95% air/5% CO2.B r i e ﬂ y ,3
× 105 cells were plated onto 12-well plates and incubated
until 80% conﬂuent, and then medium was replaced with
fresh medium containing 0.2% NuSerum and the cells were
incubated for an additional 24 hours. This medium was then
replaced with medium containing the recombinant prostasin
with or without diﬀerent agents. Cells were cultured for an
additional 3, 6, 12, 24 hours for RNA isolation or 48 hours
for aldosterone assay in the culture media.
2.4. Luciferase Reporter Assay. The human CYP11B2
promoter-luciferase construct (pB2-1521) used in the
current study was kindly provided by Bassett et al.
(University of Texas Southwestern Medical Center, Dallas,
Texas, USA) [16]. H295R cells (4.5 × 105 cells/well)
were seeded onto 12-well plate and grown to reach 50%
conﬂuency. FuGENE6 transfection reagent (Roche Applied
Science, Mannheim, Germany) was used to cotransfect
0.3pmol of pB2-1521 and 3.8fmol of pRL-TK (Promega,
Madison, WI, USA) into the cells. For the determination
of reporter activity, ﬁreﬂy luciferase activity from the pB2-
1521 and Renilla luciferase activity from the pRL-TK were
measured by the Dual Luciferase Assay System (Promega)
on a luminometer (model TD-20/20, Turner Designs Inc.,
Sunnyvale, CA, USA).
2.5. Aldosterone Assay. Aldosterone contents in the culture
media were determined by Aldosterone Express EIA Kit
(Cayman chemical, Ann Arbor, MI, USA) according to the
manufacturer’s instruction.
2.6. Real-Time PCR Analysis. T o t a lR N Aw a se x t r a c t e d
from H295R cells by using RNeasy Mini Kit (Qiagen,
Hilden, Germany). Five hundred nanograms of total RNA
was reverse-transcribed to cDNA with QuantiTect Reverse
Transcription Kit (Qiagen). TaqMan probes for human
CYP11B2, PAR-1, PAR-2, and GAPDH were all purchased
from Applied Biosystems (Foster city, CA, USA). Real-
time PCR was performed with LightCycler 480 Real-Time
PCR System (Roche Applied Science). Statistical analysis of
results was performed with the ΔCt value (Ctgene of interest-
CtGAPDH). Relative gene expression was obtained using the
ΔΔCt method (Ctsample-Ctcalibrator).
2.7. Adenovirus Construction and Infection. Adenovirus vec-
tor, Ad-hPRSS8, in which the expression of human prostasin
cDNA was under the control of the cytomegalovirus
(CMV) promoter/enhancer was constructed and prepared
by using Transpose-Ad system (Qbiogene, Illkirch, France).
Adenovirus harboring LacZ gene driven by CMV pro-
moter/enhancer (Ad-LacZ) was used as control. All viruses
were ampliﬁed in transcomplemental 293 cells and puriﬁed
by cesium chloride gradient ultracentrifugation. H295R cells
(3 × 105 cells/well) were seeded onto 12-well plate in
DMEM/F12 medium containing 2.5% UltroserSF (Biosepra,
Cergy St. Christophe, France), and 1% ITS. Three days
after seeding, cells were infected with 6 × 105 pfu/well of
adenovirus in serum-free DMEM/F12 for 1 hour, and then
the medium was replaced with DMEM/F12 containing 0.2%
NuSerum. Forty eight hours after infection, the cultureJournal of Biomedicine and Biotechnology 3
medium was collected for the detection of prostasin expres-
sion and the cells were harvested for the evaluation of the
CYP11B2 mRNA expression.
2.8. Application of siRNA. H295R cells were transfected with
human PAR-1 siRNA (Silencer Select Validated siRNA, ID:
s4923, Ambion Inc., Austin, TX, USA) or human PAR-2
siRNA (ID: s4926, Ambion) or control siRNA (ID: 4390843,
Ambion) by using Lipofectamine RNAiMAX (Invitrogen)
according to the manufacture’s instruction. Forty-eight
hours after transfection, the cells were treated with recom-
binant prostasin in DMEM/F12 with 0.2% NuSerum for 24
hours and then harvested for the total RNA isolation.
2.9. Protein Preparation and Immunoblottings. Forty-eight
hours after adenovirus infection, 200μL of culture medium
was concentrated and electrophoresed on 12% SDS-
polyacrylamide gels. The blots were probed with a mon-
oclonal antibody against prostasin (BD Biosciences) as
describedpreviously[17].Bandswerevisualizedbychemilu-
minescence substrate (ECL; Amersham Pharmacia Biotech,
Buckinghamshire, UK).
2.10. Statistical Analysis. Statistical signiﬁcance was evalu-
ated using the two-tailed, paired Student’s t-test for com-
parisons between two means, or ANOVA analysis followed
by the Newman-Keuls method for more than two means.
Av a l u eo fP<. 05 was regarded as statistically signiﬁcant.
R e s u l t sa r er e p o r t e da sm e a n± SD.
3. Results
3.1.EﬀectofProstasinonCYP11B2ExpressionandAldosterone
Production. To examine the eﬀect of prostasin on the
transcriptional activity of CYP11B2 gene, H295R cells were
transfected with pB2-1521 and treated with recombinant
prostasinfor24hours.AsshowninFigure 1(a),400μg/mLof
prostasin signiﬁcantly enhanced the transcriptional activity
of CYP11B2 by approximately 1.6-fold. Next, we determined
the endogenous mRNA expression of CYP11B2 in H295R
cells following 24-hour treatment with various concentra-
tions of prostasin. Prostasin signiﬁcantly augmented the
CYP11B2 expression in a dose-dependent manner within
a range from 100 to 400μg/mL (Figure 1(b)). We also
studied the time-course of the prostasin-mediated increase
in CYP11B2 mRNA. Cells were treated with 100μg/mL of
prostasin for 3, 6, and 24 hours, and the expression of
CYP11B2 was evaluated by the real-time PCR. Treatment
with prostasin signiﬁcantly induced CYP11B2 expression
f r o m6t o2 4h o u r s( Figure 1(c)). Furthermore, aldos-
terone contents in the culture medium were determined
following 48-hour incubation with 100μg/mL or 400μg/mL
of prostasin. As shown in Figure 1(d), prostasin dosede-
pendently stimulated aldosterone production in H295R
cells.
3.2. Adenovirus-Mediated Gene-Transfer of Prostasin in
H295R Cells Markedly Enhanced the Expression of CYP11B2
mRNA. To conﬁrm the eﬀect of prostasin on CYP11B2
expression, we infected H295R cells, which produce little
endogenous prostasin protein, with adenovirus carrying
human prostasin cDNA (Ad-hPRSS8) or control virus
carrying LacZ cDNA (Ad-LacZ). The cells infected with Ad-
hPRSS8 showed signiﬁcantly higher mRNA expression of
CYP11B2 and aldosterone production by 3.5-fold and 2.1-
fold, respectively, than the cells with Ad-LacZ (Figures 2(a)
and 2(b)). The increase in CYP11B2 expression and aldos-
terone production were comparable between adenovirus
infection and recombinant protein treatment although sig-
niﬁcantly higher amount of prostasin was applied to the cells
when treated with recombinant prostasin. Probably this may
be due to the diﬀerences in the quality and biological eﬃcacy
between the prostasin protein produced by the adenovirus-
mammalian cell system and by the baculovirus-insect cell
system.
3.3. Eﬀect of Protease-Activated Receptors (PARs) Gene Silenc-
ing on Prostasin-Induced CYP11B2 Expression in H295R Cells.
Since trypsin has been demonstrated to stimulate aldos-
terone production through the activation of PAR-1 in rat
adrenal cortex [11–14, 18], we examined if PAR is involved
in the upregulation of CYP11B2 expression by prostasin.
Because we detected both PAR-1 and PAR-2 expression
in H295R cells (data not shown), we knocked down the
expression of PAR-1 or PAR-2 by using speciﬁc siRNA and
treated the cells with 400μg/mL of prostasin for 24 hours.
The knock down eﬃciency was approximately 90% at the
mRNA levels (data not shown). As shown in Figure 2(c),
the gene silencing of either PAR-1 or PAR-2 did not abolish
the prostasin-induced CYP11B2 expression, suggesting that
PAR signaling is not involved in the prostasin-mediated
aldosterone synthesis.
3.4. Proteolytic Activity Is Not Required for the Prostasin-
Induced CYP11B2 Expression and Aldosterone Production in
H295R Cells. To determine if the proteolytic activity of
prostasin is required for the upregulation of aldosterone
synthesis, we treated H295R cells with prostasin (400μg/mL)
in the presence or absence of camostat mesilate (100μM)
which is a potent prostasin inhibitor in vitro [15, 19].
Camostat mesilate (100μM) almost completely inhibited
prostasin activity (400μg/mL) in vitro by 98.3 ± 0.8%.
Figures 3(a) and 3(b) showed that camostat mesilate had no
eﬀect on CYP11B2 expression and aldosterone production.
To conﬁrm these observations, we generated a protease-
dead mutant of recombinant prostasin and studied the
eﬀect of mutant prostasin on the aldosterone synthesis. To
our surprise, mutant prostasin (400μg/mL) substantially
increased CYP11B2 expression and aldosterone production
to the same extent as wild type prostasin (Figures 3(c) and
3(d)).
3.5. Eﬀect of Angiotensin II Type 1 Receptor Blocker (ARB),
CalciumChannelBlocker(CCB),orProteinKinaseCInhibitor
on Prostasin-Induced CYP11B2 Expression and Aldosterone
Production in H295R Cells. Next, we examined the eﬀect of4 Journal of Biomedicine and Biotechnology
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Figure 1: (a) Eﬀect of prostasin on human CYP11B2 promoter activity in H295R cells. Cells were transfected with human CYP11B2
promoter-luciferase construct (pB2-1521) for 24 hours and then treated with vehicle or prostasin for another 24 hours. (b) Dose-dependent
eﬀect of prostasin on CYP11B2 mRNA expression in H295R cells. Cells were treated with increasing doses of prostasin for 24 hours. (c)
Time course of CYP11B2 mRNA induction by prostasin in H295R cells. Cells were treated with 100¯g/mL of prostasin for 0, 3, 6, and 24
hours. (d) Dose-dependent eﬀect of prostasin on aldosterone production in H295R cells. Cells were treated with increasing concentrations
of prostasin for 48 hours. Values are means ± SD (n = 6).
∗P <. 05,
†P <. 01, and #P <. 001.
ARB, CCB, or protein kinase C inhibitor on the aldosterone
synthesis by prostasin in H295R cells. Cells were treated
with prostasin (400μg/mL) for 24 hours in the presence or
absence of valsartan (100nM), efonidipine (100nM), or a
protein kinase C ε inhibitor Ro-31-8220 (1μM). Valsartan
had no eﬀect on the prostasin-induced CYP11B2 expression
and aldosterone production, while efonidipine signiﬁcantly
reducedboth(Figures4(a)and4(b)).TreatmentwithRo-31-
8220 reduced the CYP11B2 mRNA expression to the control
levels and signiﬁcantly inhibited the aldosterone production
(Figures 4(c) and 4(d)).
4. Discussion
In the current studies, we demonstrated the following
ﬁndings: (1) prostasin increased the transcriptional activ-
ity of CYP11B2 promoter in H295R cells, (2) prostasin
increased both CYP11B2 mRNA expression and aldos-
terone production in H295R cells in a time and dose-
dependent manner, (3) augmentation of both CYP11B2
mRNA expression and aldosterone production was indepen-
dentoftheproteolyticactivityofprostasin,and(4)induction
of CYP11B2 expression and aldosterone production byJournal of Biomedicine and Biotechnology 5
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Figure 2: Eﬀect of adenovirus-mediated overexpression of prostasin on CYP11B2 expression (a) and aldosterone production (b) in H295R
cells. Cellswere infected with 6 × 105 pfu of control virus (Ad-LacZ) or adenovirus carrying human prostasin (Ad-hPRSS8)for 1 hour. Forty
eight hours after infection, total RNA was isolated for the real time PCR and the medium was collected for the aldosterone measurement.
(c) Eﬀect of PAR-1 or PAR-2 knock down on prostasin-induced CYP11B2 expression in H295R cells. Cells were transfected with siRNA for
either PAR-1 or PAR-2 for 48 hours and then treated with prostasin for another 24 hours. mRNA expression of CYP11B2 was determined by
the real time PCR. Values are means ± SD (n = 6).
∗P <. 001 versus Ad-LacZ (a), (b), or vehicle (c).
prostasin was blocked by the Ca2+ channel blocker and the
PKCinhibitor.Theseresultssuggestthatprostasinmightplay
a regulatory role in the aldosterone production by adrenal
grand.
Previously we reported that aldosterone increased
prostasin abundance in rat and human [3]. Wang et al.
demonstrated that adenovirus-mediated human prostasin
gene delivery resulted in an increase in plasma prostasin and
a l d o s t e r o n el e v e l sa sw e l la sa ne l e v a t i o ni nb l o o dp r e s s u r e
in rat [5]. These ﬁndings suggest the possibility that there
may be a positive feedback regulation in the aldosterone
production by prostasin. To elucidate the eﬀect of the
elevated circulating plasma prostasin levels on aldosterone
production by adrenal gland, we generated recombinant
prostasin protein and studied the eﬀect of prostasin on
aldosterone production in H295R cells. Previous studies in
the early 1980s described the stimulatory eﬀect of trypsin
on aldosterone secretion from rat adrenal zona glomerulosa
[11–13]. In addition, trypsin has been shown to activate
PAR-1 and thereby stimulate aldosterone secretion from
adrenal zona glomerulosa [14]. These studies suggest the
possibility that trypsin-like serine proteases such as prostasin
may be able to stimulate aldosterone production from
adrenal gland. In the present studies, we demonstrated
that treatment of H295R cells with prostasin signiﬁcantly
increased both CYP11B2 mRNA expression and aldosterone
production in a dose-dependent manner. Since the speciﬁc
activity of our recombinant prostasin against synthetic
substrate is approximately 30-fold lower than the native
prostasin puriﬁed from human seminal ﬂuid (data not
shown), the concentration of recombinant prostasin used
for the current studies is relatively higher than the serum6 Journal of Biomedicine and Biotechnology
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Figure 3: Prostasin increases CYP11B2 expression and aldosterone production independently of its proteolytic activity in H295R cells. (a)
CYP11B2 expression was measured following 24-hour treatment with prostasin in the presence or absence of 100¯M camostat mesilate
(CM). (b) Aldosterone production was determined following 48-hour treatment with prostasin in the presence or absence of 100¯M CM.
(c) CYP11B2 expression was measured following 24-hour treatment with protease-dead mutant prostasin. (d) Aldosterone production was
determined following 48-hour treatment with mutant prostasin. Values are means ± SD (n = 6).
∗P <. 001 versus vehicle.
prostasin concentration reported by Mok et al. However,
contrary to our expectations, treatment with camostat
mesilate, a potent prostasin inhibitor [15, 19], had no
eﬀect on the prostasin-induced aldosterone synthesis. In
addition, the protease-dead mutant of prostasin signiﬁcantly
stimulatedCYP11B2expressionandaldosteroneproduction.
These ﬁndings suggest that the protease activity is not
primarily required for the prostasin-induced aldosterone
synthesis in H295R cells. In the current studies, we used
recombinanthumanprostasingeneratedbyaninsectexpres-
sion system. We speculate that our recombinant protein may
have diﬀerent glycosylation modiﬁcation or may contain
misfolded proteins from the native prostasin due to the
non-mammalian and forced expression system. As a result,
our recombinant prostasin had lower speciﬁc activities,
suggesting that our recombinant prostasin may have lower
biological eﬃcacy as well. Therefore, we think that our
recombinant prostasin required relatively higher concentra-
tions of proteins to observe the aldosterone synthesis in
H295R cells. We also tested the eﬀects of residue reagents
to exclude the possibility that contaminant materials in the
recombinant prostasin stimulated the aldosterone synthesis.
We manipulated noninfected silkworm hemolymph exactly
the same way as infected hemolymph and used as a
control, but we did not observe any signiﬁcant aldosterone
synthesis in H295R cells (data not shown). Our ﬁndings
that the gene silencing of either PAR-1 or PAR-2 had
no eﬀect on the prostasin-mediated increase in CYP11B2
expression may also support the nonproteolytic eﬀect of
prostasin. Because we were not able to demonstrate anyJournal of Biomedicine and Biotechnology 7
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Figure 4: Eﬀect of angiotensin II type 1 receptor blocker (a) and (b), T-type/L-type Ca
2+ channel blocker (a) and (b), or PKCε inhibitor
(c) and (d) on the prostasin-induced CYP11B2 expression and aldosterone production in H295R cells. Cells were treated with prostasin
(400μg/mL) in the presence or absence of valsartan (100nM), efonidipine (100nM), or Ro-31-8220 (1¯M). CYP11B2 mRNA expression (a)
and (c) was determined following 24-hour treatment, and aldosterone production (b) and (d) was evaluated following 48-hour treatment.
Values are means ± SD (n = 6).
∗P <. 001 versus vehicle. n.s.: not signiﬁcant.
importance of the catalytic activity of prostasin on the
aldosterone synthesis, we propose a direct protein-protein
interaction between prostasin and unidentiﬁed membrane
molecules such as transmembrane receptors. Noncatalytic
biologic function in serine proteases has been illustrated by
the hepatocyte growth factor and macrophage stimulatory
protein hormones, both of which have lost their catalytic
function but interact with transmembrane tyrosine kinase
receptorstoinduceintercellularsignalingcascades[20].Also,
Chen et al. reported the nonproteolytic function of prostasin
in the regulation of mRNA expression of urokinase-type
plasminogen activator (uPA) and inducible nitric oxide
synthase (iNOS) in PC-3 human prostate carcinoma cells
[21], although they did not elucidate the precise mechanism
by which prostasin mediates its signal to the intracellular
targets. Further investigations are deﬁnitely required to
identify the target molecules for the extracellular prostasin
to transmit its signal to the intracellular molecules leading to
the activation of aldosterone synthesis.
Because the aldosterone synthesis is regulated by
angiotensin II through the angiotensin II type 1 receptor
(AT-1R) in normal human adrenocortical cells [22, 23],
the ﬁrst target molecule that we examined was AT-1R. We
hypothesized that prostasin may transactivate the AT-1R in
some way leading to the stimulation of CYP11B2 expression.
However, since the treatment with valsartan did not abolish
the aldosterone synthesis by prostasin, it is unlikely that
angiotensin II signaling participates in this mechanism.
Calcium inﬂux through the plasma membrane has been
shown to mediate the expression of mRNAs for CYP11B1
and CYP11B2, especially CYP11B2, in H295R cells. mRNA
expression of these enzymes was suppressed by L-type Ca2+
channel blockers, indicating that L-type Ca2+ channels may
be involved in the steroid biosynthesis in adrenocortical
cells [24–26]. In addition, the earlier studies suggested
the possible involvement of T-type Ca2+ channel activity
in aldosterone biosynthesis in bovine adrenal glomerulosa
cells [27]. Recently, efonidipine and benidipine, which are8 Journal of Biomedicine and Biotechnology
dual (T-type/L-type) Ca2+ channel blockers, have been
demonstrated to inhibit aldosterone biosynthesis in H295R
cells more potently than the L-type Ca2+ channel blocker
nifedipine [28, 29]. In the current studies, we showed that
efonidipine, a T-type/L-type Ca2+ channel blocker, exerted
an inhibitory eﬀect on steroid biosynthesis by prostasin in
H295R cells, suggesting the involvement of these channels
in the aldosterone production by prostasin. Several PKC
isozymes have been reported to mediate endogenous PKCμ
activation. Romero et al. showed that PKCε has a critical
role in PKC¯ activation in human adrenal cells and PKCμ
activation by angiotensin II caused a remarkable upregula-
tion of aldosterone synthase gene expression in H295R cells
[30]. They also showed that a PKCε inhibitor Ro-31-8220
inhibited the phosphorylation of PKCμ. We demonstrated
that Ro-31-8220 signiﬁcantly reduced the aldosterone syn-
thesis by prostasin, suggesting the involvement of PKCε in
the prostasin-mediated aldosterone synthesis pathway.
Inconclusions,wedemonstratedthatprostasinincreased
aldosterone production in H295R cells, probably via non-
proteolytic action of prostasin, and that T-type/L-type
calcium channels and PKCε are at least involved in the
aldosterone synthesis by prostasin. Although the precise
mechanism by which extracellular prostasin transmits its
signal to the intracellular molecules remains unknown, our
current data will provide a new insight into the role of
prostasin, especially that in the systemic circulation, in the
regulatory mechanisms of aldosterone production by the
adrenal gland. Also, our current ﬁndings, together with our
previous reports, suggest the possibility that there may be
a vicious cycle between prostasin and aldosterone although
further intensive in vivo studies are required to elucidate the
physiological roles of prostasin in the systemic circulation.
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